The central contribution of SMA models to the development of SMA therapies was instigated by the fact that they reflected key features of severe SMA: a short lifespan and severe motor neuron pathology that could be (partially) rescued by restoring SMN expression. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.